Bactiguard plans initial public offering (IPO) on NASDAQ OMX Stockholm
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN.
The Board of Directors of Bactiguard Holding AB (publ) (“Bactiguard”) confirms its intention to proceed with an IPO of Bactiguard on NASDAQ OMX Stockholm. Subject to necessary decisions being taken, receipt of NASDAQ OMX Stockholm approval and determination of favourable market conditions, the IPO is expected to take place in late June 2014.
“The planned IPO is an important milestone for Bactiguard and an important step in creating a long-term platform for the company’s continued development. A listing will contribute positively to the company's growth opportunities and make Bactiguard’s efforts to prevent healthcare-associated infections better known among customers, the media and investors,” says Johan Rugfelt, CEO of Bactiguard.
The offer to acquire shares in Bactiguard will cover newly issued shares as well as existing shares. The shares will be offered to Swedish and international institutional investors and, in a retail offering, to the general public in Sweden.
Prior to the planned IPO, holders of Bactiguard’s corporate bonds will be contacted individually by Bactiguard and offered the option to offset their bonds against Bactiguard shares, contingent upon completion of the IPO.
Swedbank has been appointed Lead Manager and Sole Bookrunner and ABG Sundal Collier have been appointed Co-Lead Managers in connection with the intended IPO. Cederquist is legal advisor.
Bactiguard Holding AB (publ) is required to disclose the above information under the provisions of the Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8:00 AM CET on 23 May 2014 .
Johan Rugfelt - CEO
johan.rugfelt@bactiguard.com
+46 708 724 739
Cecilia Edström - Director of Communications
cecilia.edstrom@bactiguard.com
+46 722 262 328
Bactiguard
Bactiguard is a Swedish medtech company with a business concept of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia.
Tags: